Diet is a modifiable key factor targeted in prevention and management of nonalcoholic fatty liver disease (NAFLD). The aim was to study the effect of Mediterranean Diet (MedDiet) on clinical, biochemical, and inflammatory profile in NAFLD patients with simple steatosis. Potential associations of signal transducer and activator of transcription 3 (STAT3) rs2293152 genotype to diet composition and patients' profile were investigated. In this nonrandomized, open-label, 24-week prospective intervention study, 44 untreated NAFLD patients with nonsignificant fibrosis received nutritional counsel to increase adherence to MedDiet. Adherence to MedDiet was estimated with MedDietScore. Furthermore, we genotyped STAT3 rs2293152 single nucleotide polymorphism and performed clinical and inflammatory measurements. In all patients, MedDietScore increased and anthropometric indices improved, whereas liver imaging, liver fibrosis score, blood pressure, fasting glucose, glycated hemoglobin (HbA1c), C-reactive protein (CRP), visfatin, and oxidized low-density lipoprotein levels were also significantly ameliorated compared with baseline (P < .05). No association of STAT3 polymorphism with diet composition was found. Comparisons of mean differences between G- and C-carriers at the end point of the trial showed that only visfatin was significantly associated with the STAT3 genotype (−0.0 ± 4.6 vs. −4.2 ± 3.9, P = .04, respectively). Carrying the G-allele was associated with an increase of the visfatin levels (3.4 ± 1.5 ng/mL, P = .028). Our results show amelioration of clinical, biochemical, and inflammatory biomarkers in NAFLD patients in response to MedDiet. STAT3 rs2293152 G-carriers experienced more beneficial changes at the end of the intervention compared with baseline. An association between visfatin levels and STAT3 genotype has been shown for the first time.
Get full access to this article
View all access options for this article.
References
1.
YounossiZM, StepanovaM, AfendyM, FangY, YounossiY, MirH, et al.: Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol, 2011; 9:524–530.
2.
FargionS, PorzioM, FracanzaniAL: Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol, 2014; 20:13306–13324.
3.
LoombaR, SanyalAJ: The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol, 2013; 10:686–690.
4.
BugianesiE, LeoneN, VanniE, MarchesiniG, BrunelloF, CarucciP, et al.: Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology, 2002; 123:134–140.
5.
HallsworthK, AveryL, TrenellMI: Targeting lifestyle behavior change in adults with NAFLD during a 20-min consultation: Summary of the dietary and exercise literature. Curr Gastroenterol Rep, 2016; 18:11.
6.
BarattaF, PastoriD, PolimeniL, BucciT, CeciF, CalabreseC, et al.: Adherence to Mediterranean Diet and non-alcoholic fatty liver disease: Effect on insulin resistance. Am J Gastroenterol, 2017; 112:1832–1839.
7.
RyanMC, ItsiopoulosC, ThodisT, WardG, TrostN, HofferberthS, et al.: The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol, 2013; 59:138–143.
8.
KalioraAC, KokkinosA, DiolintziA, StoupakiM, GioxariA, KanellosPT, et al.: The effect of minimal dietary changes with raisins in NAFLD patients with non significant fibrosis, a randomized controlled intervention. Food Funct, 2016; 7:4533–4554.
9.
PanJJ, FallonMB: Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol, 2014; 6:274–283.
10.
WoodKL, MillerMH, DillonJF: Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease. BMJ Open Gastroenterol, 2015; 2:e000019.
11.
LimJW, DillonJ, MillerM: Proteomic and genomic studies of non-alcoholic fatty liver disease—Clues in the pathogenesis. World J Gastroenterol, 2014; 20:8325–8340.
12.
KalafatiIP, BorsaD, DedoussisGVZ: The genetics of nonalcoholic fatty liver disease: Role of diet as a modifying factor. Curr Nutr Rep, 2014; 3:223–232.
13.
SookoianS, CastañoG, GianottiTF, GemmaC, RosselliMS, PirolaCJ: Genetic variants in STAT3 are associated with nonalcoholic fatty liver disease. Cytokine, 2008; 44:201–206.
14.
HeG, KarinM: NF-kappaB and STAT3—Key players in liver inflammation and cancer. Cell Res, 2011; 21:159–168.
15.
KeysA: Mediterranean diet and public health: Personal reflections. Am J Clin Nutr, 1995; 61(6Suppl):1321S–1323S.
16.
DavisJE, McDonaldJM, JarettL: A high-performance liquid chromatography method for hemoglobin A1c. Diabetes, 1978; 27:102–107.
17.
AnguloP, HuiJM, MarchesiniG, BugianesiE, GeorgeJ, FarrellGC, et al.: The NAFLD Fibrosis Score, a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007; 45:846–854.
18.
EsterbauerH, JurgensG: Mechanistic and genetic aspects of susceptibility of LDL to oxidation. Curr Opin Lipidol, 1993; 4:114–124.
19.
PanagiotakosDB, PitsavosC, ArvanitiF, StefanadisC: Adherence to the Mediterranean food pattern predicts the prevalence of hypertension, hypercholesterolemia, diabetes and obesity, among healthy adults, the accuracy of the MedDietScore. Prev Med, 2007; 44:335–340.
20.
AbenavoliL, MilicN, PetV, AlfieriF, De LorenzoA, BellentaniS: Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol, 2014; 20:16831–16840.
21.
BarreraF, GeorgeJ: The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis, 2014; 18:91e112.
22.
MascitelliL, GoldsteinMR: Might some of the beneficial effects of the Mediterranean diet on non-alcoholic fatty liver disease be mediated by reduced iron stores?. J Hepatol, 2013; 59:639.
23.
BellantiF, VillaniR, FacciorussoA, VendemialeG, ServiddioG: Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. Free Radic Biol Med, 2017; 111:173–185.
24.
PolimeniL, Del BenM, BarattaF, PerriL, AlbaneseF, PastoriD: Oxidative stress: New insights on the association of nonalcoholic fatty liver disease and atherosclerosis. World J Hepatol, 2015; 7:1325–1336.
25.
SöderbergC, StålP, AsklingJ, GlaumannH, LindbergG, MarmurJ, et al.: Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology, 2010; 51:595–602.
26.
BaskolG, BaskolM, KocerD: Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochem, 2007; 40:776–780.
27.
ShimomuraY, TakakiA, WadaN, YasunakaT, IkedaF, MaruyamaT, et al.: The serum oxidative/anti-oxidative stress balance becomes dysregulated in patients with non-alcoholic steatohepatitis associated with hepatocellular carcinoma. Intern Med, 2017; 56:243–251.
28.
IrieM, SohdaT, IwataK, KunimotoH, FukunagaA, KunoS, et al.: Levels of the oxidative stress marker γ-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease. J Int Med Res, 2012; 40:924–933.
29.
SabatineMS, MorrowDA, JablonskiKA, RiceMM, WarnicaJW, DomanskiMJ, et al.: PEACE Investigators. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation, 2007; 115:1528–1536.
30.
SantosAC, LopesC, GuimarãesJT, BarrosH: Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes (Lond), 2005; 29:1452–1456.
31.
RidkerPM, BuringJE, CookNR, RifaiN: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation, 2003; 107:391–397.
32.
NealeEP, BatterhamMJ, TapsellLC: Consumption of a healthy dietary pattern results in significant reductions in C-reactive protein levels in adults: A meta-analysis. Nutr Res, 2016; 36:391–401.
33.
LeeJ, YoonK, RyuS, ChangY, KimHR: High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men. PLoS One, 2017; 12:e0172666.
34.
KitabatakeH, TanakaN, FujimoriN, KomatsuM, OkuboA, KakegawaK, et al.: Association between endotoxemia and histological features of nonalcoholic fatty liver disease. World J Gastroenterol, 2017; 23:712–722.
35.
ForoughiM, MaghsoudiZ, KhayyatzadehS, GhiasvandR, AskariG, IrajB: Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. Adv Biomed Res, 2016; 5:28.
36.
StojsavljevićS, Gomerčić PalčićM, Virović JukićL, Smirčić DuvnjakL, DuvnjakM: Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol, 2014; 20:18070–18091.
37.
DedoussisGV, KapiriA, SamaraA, DimitriadisD, LambertD, PfisterM, SiestG, Visvikis-SiestS: Visfatin: The link between inflammation and childhood obesity. Diabetes Care, 2009; 32:e71.
38.
Paredes-TurrubiarteG, González-ChávezA, Pérez-TamayoR, Salazar-VázquezBY, et al.: Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients. Clin Exp Med, 2016; 16:193–202.
39.
WieckowskaA, PapouchadoBG, LiZ, LopezR, ZeinNN, FeldsteinAE: Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol, 2008; 103:1372–1379.
40.
SubramaniamA, ShanmugamMK, PerumalE, LiF, NachiyappanA, DaiX, et al.: Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta, 2013; 1835:46–60.
PhillipsCM, GoumidiL, BertraisS, FieldMR, PelosoGM, ShenJ, et al.: Dietary saturated fat modulates the association between STAT3 polymorphisms and abdominal obesity in adults. J Nutr, 2009; 139:2011–2017.
43.
MaZ, WangG, ChenX, OuZ, ZouF: Association of STAT3 common variations with obesity and hypertriglyceridemia: Protective and contributive effects. Int J Mol Sci, 2014; 15:12258–12269.
44.
GianottiTF, SookoianS, GemmaC, BurgueñoAL, GonzálezCD, PirolaCJ: Study of genetic variation in the STAT3 on obesity and insulin resistance in male adults. Obesity (Silver Spring), 2008; 16:1702–1707.
45.
SlatteryML, LundgreenA: The influence of the CHIEF pathway on colorectal cancer-specific mortality. PLoS One, 2014; 9:e116169.
46.
YuanK, LiuH, HuangL, RenX, LiuJ, DongX, et al.: rs744166 polymorphism of the STAT3 gene is associated with risk of gastric cancer in a Chinese population. Biomed Res Int, 2014; 2014:527918.
47.
CénitMC, Ortego-CentenoN, RayaE, CallejasJL, García-HernandezFJ, Castillo-PalmaMJ, et al.: Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcet's disease. Hum Immunol, 2013; 74:230–233.
48.
XiaoL, MuhaliFS, CaiTT, SongRH, HuR, ShiXH, et al.: Association of single-nucleotide polymorphisms in the STAT3 gene with autoimmune thyroid disease in Chinese individuals. Funct Integr Genomics, 2013; 13:455–461.
49.
LillCM, SchjeideBM, AkkadDA, BlaschkeP, WinkelmannA, GerdesLA, et al.: Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample. Neurogenetics, 2012; 13:83–86.
50.
SatoK, ShiotaM, FukudaS, IwamotoE, MachidaH, InamineT, et al.: Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn's disease in the Japanese population. J Clin Immunol, 2009; 29:815–825.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
